China's First Gene Therapy Struggles to Find Buyers Despite Price Cut

Key facts

• Xinjiuning is China's first approved gene therapy for hemophilia.
• The therapy was developed by Belief BioMed Co. Ltd.
• Xiao Xiao, co-founder and chairman of Belief BioMed, has been trying to sell the treatment.

Belief BioMed Co. Ltd.'s gene therapy for hemophilia, named Xinjiuning, is struggling to find buyers in China. The company has spent years developing the treatment, which is the first of its kind approved in the country for the rare condition that affects blood clotting. Xiao Xiao, co-founder and chairman of Belief BioMed, has been actively attempting to sell the therapy despite a price cut.